Atlas Trials

Relmada Therapeutics, Inc.

11 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Relmada Therapeutics, Inc.

RecordFirmDate
A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy (NCT07342517)Relmada Therapeutics, Inc.2026-06-30
A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer (NCT07464145)Relmada Therapeutics, Inc.2026-06-01
A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT (NCT07313891)Relmada Therapeutics, Inc.2026-05-01
Open Label Study to Evaluate the Safety and Efficacy of NDV01 KIT in High Grade NMIBC (NCT06663137)Relmada Therapeutics, Inc.2024-08-01
A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD) (NCT05081167)Relmada Therapeutics, Inc.2021-06-02
Safety of REL-1017 for Major Depressive Disorder (NCT04855760)Relmada Therapeutics, Inc.2021-04-01
A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD) (NCT04688164)Relmada Therapeutics, Inc.2021-01-08
Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD (NCT03051256)Relmada Therapeutics, Inc.2018-05-11

Track Relmada Therapeutics, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.